Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Jay Flatley, Tristan Orpin, Christian Henry, Greg Heath, Greg Yap, and More

Premium

Illumina recently announced a reorganization, accompanied by changes in managerial duties, that will take effect on Jan. 1, 2014.

President and CEO Jay Flatley will continue to serve as CEO, but the company will separate the two positions and appoint a new president.

The company is also reorganizing into five business units. Kirk Malloy, currently vice president of Customer Solutions will head the Life Sciences business unit. Tristan Orpin, currently chief commercial officer, will head the Reproductive and Genetic Health business unit. Christian Henry, currently SVP and general manager of the Genomic Solutions business will take over as chief commercial officer.

Rick Klausner, Illumina's chief medical officer, will serve as interim leader of the Oncology business unit. Nick Naclerio will head the Enterprise Informatics business unit, while continuing in his current role as SVP of corporate development. And Matt Posard will lead Illumina's newly created New and Emerging Markets business unit. Posard is currently SVP and general manager of Illumina's Translational and Consumer Genomics business.

Additionally, Greg Heath will move from his position as SVP and general manager of Illumina's Diagnostics business unit to SVP of IVD Development. Bob Ragusa will join the company in December as SVP of Operations.

Quality and Regulatory Affairs will become two separate functions with Regulatory Affairs being folded into IVD Development. Melina Cimler will serve as VP of Quality.


Greg Yap has been named CEO and a director of protein analysis company Biodesy.

Previously, Yap held several management roles at Affymetrix, including vice president of DNA products and vice president of molecular diagnostics. More recently, he was the first healthcare entrepreneur in residence at GE, and was lifecycle leader of advanced staining assays at Ventana Medical Systems.


Sid Taubenfeld has joined Arrayit's board of directors.

Taubenfeld has served as an analyst for a number of Wall Street hedge funds, including Balyasny Asset Management, RH Capital, and PAW Partners. Additionally, Taubenfeld served as director of communications and strategic initiatives for Celsion Corp.

The Scan

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.

DNA Biobank Developed for French Kidney Donors, Recipients

The KiT-GENIE biobank described in the European Journal of Human Genetics contains DNA samples, genotyping profiles, immune patterns, and clinical features for thousands of kidney donors or transplant recipients in Nantes, France.

Cardiometabolic Disease May Have Distinct Associations With Microbial Metabolites in Blood, Gut

By analyzing gut microbes in combination with related metabolites in feces and blood, researchers in Nature Communications found distinct cardiometabolic disease relationships at each site.

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.